Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663393 | 0.93 | KMT2A (0.56) | MAPTKMT2APOLBPKMMEN1 | |
| SCHEMBL3660062 | 0.88 | KMT2A (0.55) | KMT2APOLBMEN1 | |
| SCHEMBL3662112 | 0.88 | KCNH2 (0.57) | MAPTKMT2AMEN1 | |
| SCHEMBL3660498 | 0.85 | KMT2A (0.61) | MAPTKMT2APOLBPKMMEN1 | |
| SCHEMBL4122445 | 0.81 | KMT2A (0.55) | MAPTKMT2APOLBPKMMEN1 | |
| SCHEMBL3659945 | 0.80 | TSHR (0.56) | MAPTKMT2AMEN1USP2CRHBP | |
| SCHEMBL3796712 | 0.79 | HDAC6 (0.46) | MAPTKMT2APOLBPKMMEN1 | |
| SCHEMBL3657913 | 0.79 | MAPT (0.50) | MAPTKMT2APOLBPKMMEN1 | |
| SCHEMBL3656018 | 0.76 | KMT2A (0.51) | KMT2APOLBMEN1 | |
| SCHEMBL3659738 | 0.76 | POLB (0.56) | KMT2APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101827840-A | Imidazolidine-2,4-dione (hydantoin) derivatives useful as npy y2 receptor modulators | NOVARTIS AG | 2010-09-08 | — | — | CN | disclosed |
| EP-2212314-A1 | IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050200-A1 | IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099243-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099243-A1 | ORGANIC COMPOUNDS | SLCO4C1, SLCO1B1, SLCO1B3 | MAPT 895/4885KMT2A 2020/4885POLB 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.